| Bioactivity | CHD1Li 6.11 is a potent oncogenic CHD1L inhibitor (IC50=3.3 µM for cat-CHD1L recombinant protein). CHD1Li 6.11 is an orally bioavailable antitumor agent, significantly reducing the tumor volume of CRC xenografts generated from isolated quasi mesenchymal cells (M-phenotype), which possess enhanced tumorigenic properties[1]. | ||||||||||||
| Name | CHD1Li 6.11 | ||||||||||||
| CAS | 2716890-91-2 | ||||||||||||
| Formula | C21H22BrN5OS | ||||||||||||
| Molar Mass | 472.40 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Prigaro BJ, et al. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022;65(5):3943-3961. |
CHD1Li 6.11
CAS: 2716890-91-2 F: C21H22BrN5OS W: 472.40
CHD1Li 6.11 is a potent oncogenic CHD1L inhibitor (IC50=3.3 µM for cat-CHD1L recombinant protein).CHD1Li 6.11 is an ora
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.